Bibliography
- Cohen P, Alessi DR. Kinase drug discovery – what's next in the field? ACS Chem Biol 2013;8:96–104
- Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Disc 2002;1:493–502
- Nelson V, Altman JK, Plantanias LC. Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. Expert Opin Investig Drugs 2013;22(6):715–22
- Turajlic S, Ali Z, Yousaf N, Larkin J. Phase I/II RAF kinase inhibitors in cancer therapy. Expert Opin Investig Drugs 2013;22(6):739–49
- Bose P, Simmons G, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 2013;22(6):723–38
- Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs 2013;22(6):687–99
- Lang F, Voelkl J. Therapeutic potential of serum and glucocorticoid inducible kinase inhibition. Expert Opin Investig Drugs 2013;22(6):701–14
- Prada PO, Saad MJA. Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes. Expert Opin Investig Drugs 2013;22(6):751–63
- Rosenberg A, Mathew P. Imatinib and prostate cancer: lessions learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs 2013;22(6):787–94
- King JW, Lee SM. Axitinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Investig Drugs 2013;22(6):765–73
- Derenzini E, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. Expert Opin Investig Drugs 2013;22(6):775–85
- Scher KS, Solmo G. Dasatinib: a novel therapy for breast cancer? Expert Opin Investig Drugs 2013;22(6):795–801
- Bamborough P. System-based drug discovery within the human kinome. Expert Opin Drug Discov 2012;9(7):1053–70
- O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401–12